Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Debapriya RoyMahapatra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, Kolkata 700 026, West Bengal, India. Hauptthemen laut MEDLINE: Neoplasms, Lymphoma, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Indian Council of Medical Research, Chittaranjan National Cancer Institute, Ministry of Human Resource Development.
Abstract (Originalsprache)
Lymphoma can effectively be treated with a chemotherapy regimen that is associated with adverse side effects due to increasing drug resistance, so there is an emergent need for alternative small-molecule inhibitors to overcome the resistance that occurs in lymphoma management and overall increase the prognosis rate. A new series of substituted naphthalimide moieties conjugated via ester and amide linkages with artesunate were designed, synthesized, and characterized. In addition to the conjugates, to further achieve a theranostic molecule, FITC was incorporated via a multistep synthesis process. DNA binding studies of these selected derivatives by ultraviolet-visible (UV-vis), fluorescence spectroscopy, intercalating dye (EtBr, acridine orange)-DNA competitive assay, and minor groove binding dye Hoechst 33342-DNA competitive assay suggested that the synthesized novel molecules intercalated between the two strands of DNA due to its naphthalimide moiety and its counterpart artesunate binds with the minor groove of DNA. Napthalimide-artesunate conjugates inhibit the growth of lymphoma and induce apoptosis, including ready incorporation and reduction in cell viability. The remodeled drug has a significant tumoricidal effect against solid DL tumors developed in BALB/c mice in a dose-dependent manner. The novel drug appears to inhibit metastasis and increase the survival of the treated animals compared with untreated littermates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Translational Research, Chittaranjan National Cancer Institute, Kolkata 700 026, West Bengal, India.
- Immunobiology Laboratory, Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
ORCID-Profile: Ugir Hossain Sk, Partha Pratim Manna
Förderung
- Indian Council of Medical Research
- Chittaranjan National Cancer Institute
- Ministry of Human Resource Development
- Human Resource Development Group
Zitieren
APA
RoyMahapatra, D., Singh, R., Sk, U. H., & Manna, P. P. (2024). Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00632
Vancouver
RoyMahapatra D, Singh R, Sk UH, Manna PP. Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00632
BibTeX
@article{RoyMahapatra2024,
author = {RoyMahapatra, Debapriya and Singh, Ranjeet and Sk, Ugir Hossain and Manna, Partha Pratim},
title = {Engineered Artesunate-Naphthalimide Hybrid Dual Drug for Synergistic Multimodal Therapy against Experimental Murine Lymphoma},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00632}
}
EUVIMED